Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab in Indian Patients with nAMD
NCT05269966Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2022
- Primary completion
- Aug 2023
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Primary endpoint: Incidence and Characteristics of Treatment-emergent Adverse Events at 56 weeks. Started Mar 2022; status: completed.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05269966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05269966.